THE RADIANT CREATIONS GROUP, INC.

Annual Report for the period February 29, 2016 and February 28, 2015

ITEM 1 - NAME OF ISSUER AND ITS PREDECESSORS (if any):

The Radiant Creations Group, Inc. – 7/16/2013 to present
Formerly – Nova Mining Corporation 12/29/2005 to 7/16/2013

ITEM 2 - ADDRESS OF THE ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

Center for Innovation
10380 SW Village Center Drive
Suite 352
Port Saint Lucie, FL
Phone: (772) 380-4320
www.radiantcreationsgroup.com

ITEM 3 - SECURITY INFORMATION:

As of February 29, 2016 and February 28, 2015:

Trading symbol: RCGP

Common Stock – 900,000,000 shares authorized, par value $.00001 and 23,137,979 and 56,013 shares issued and outstanding, respectively.

Series A Preferred Stock – 3,000,000 shares authorized, par value $.00001 and 3,000,000 and 1,000,000 shares issued and outstanding, respectively.

Series B Preferred Stock – 100,000,000 shares authorized, par value $.00001 and 20,000,000 and 20,000,000 shares issued and outstanding, respectively.

Cusip number: 750248 205

Transfer Agent:

Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
801-274-1088
http://www.actionstocktransfer.com

This transfer Agent is registered under the Exchange Act

ITEM 4 - ISSUANCE HISTORY

During the year ended February 29, 2016, the Company issued 282,944 shares of common stock upon the conversion of debt, for an aggregate value of $182,539.

During the year ended February 29, 2016, the Company issued 12,600 shares of common stock in connection with the issuance of a note payable.

During the year ended February 29, 2016, the Company issued 18,196,422 shares of common stock for cash for a value of $130,140.

During the year ended February 29, 2016, the Company converted $537,000 in accrued executive compensation to 4,590,000 shares of common stock of the Company.

During the year ended February 29, 2016, the Company received $100,000 from an investor in exchange for shares of common stock in the Company equal to 5% of the total outstanding shares of common stock as of January 31, 2016. As of February 29, 2016, 1,683,000 shares have been issued.
During the year ended February 29, 2016, the Company issued 2,000,000 shares of its Series A Preferred Stock to related parties as consideration for the purchase of intellectual property. The fair value of the shares of $17,800, based on the value of the control feature, was recorded as expense during the year ending February 29, 2016.

During the twelve months ended February 28, 2015, the Company issued 25,604 shares of common stock upon the conversion of debt, for an aggregate value of $215,150.

During the twelve months ended February 28, 2015, the Company issued 2,992 shares of common stock as compensation for services for a value of $19,524.

Prior to the twelve months ended February 28, 2015, the Company granted 30,440 options to employees and directors with a term of 5 years and are exercisable at prices ranging from $0.098 to $0.127 per share. 8,000 options vested immediately while the remaining 22,440 options vest at a rate of 33% on the grant date, 33% one year from the grant date and the remaining 33% two years from the grant date. The fair value of the options was determined using a Black Scholes model. The total grant date fair value of the options amounted to $3,630,278 of which $414,517 and $3,193,006 was recorded as stock compensation expense during the twelve months ended February 29, 2016 and February 28, 2015, respectively.

On September 9, 2014 and October 13, 2014 Biodynamic Molecular Technologies, LLC (a commonly controlled shareholder) agreed to cancel a total of 16,000 common shares of the Company in exchange for 1,000,000 shares of Series A Preferred stock and 20,000,000 shares of Series B Preferred stock.

The Company estimated the fair value of the 20,000,000 shares of common stock based on the trading price on date of the exchange, and the fair value of the preferred stock using a probability weighted expected return method (PWERM) and recorded expense equal to the excess of the fair value of the preferred stock over the common stock of $476,000, which is included in loss on acquisition of intellectual property from a commonly controlled entity on the consolidated statements of operations.

Stock compensation expense totaled $978,724 and $3,212,910 for the twelve months ended February 29, 2016 and February 28, 2015, respectively.

<u>NIT Enterprises, Inc.</u>

During the year ended February 29, 2016, NIT Enterprises issued 110,000 shares of common stock as compensation for services rendered for a value of $11.

During the year ended February 29, 2016, NIT Enterprises issued 4,092,000 shares of common stock for cash for a value of $1,038,970.

During the year ended February 29, 2016, NIT Enterprises issued 30,982,000 preferred shares to investors according to the terms provided in NIT's cash subscription agreement. The shares were issued at par value.

During the year ended February 29, 2016, NIT Enterprises issued 1,000,000 Series A, Super-Voting preferred shares to a founder for a value of $100.

During the year ended February 29, 2015, NIT Enterprises issued 3,800,000 shares of common stock for services rendered for a value of $380.

During the year ended February 29, 2015, NIT Enterprises issued 560,000 shares of common stock for cash for a value of $150,002.

During the year ended February 29, 2015, NIT Enterprises issued 560,000 preferred shares to investors according to the terms provided in NIT's cash subscription agreement. The shares were issued at par value.

ITEM 5 FINANCIAL STATEMENTS

The Radiant Creations Group, Inc.
Consolidated Financial Statements
February 29, 2016 and February 28, 2015

THE RADIANT CREATIONS GROUP, INC.
CONSOLIDATED BALANCE SHEETS

	February 29, 2016	February 28, 2015
ASSETS		
Cash	$ 2,433	$ 15,293
Accounts receivable reserve	95,524	75,447
Prepaid expenses and other assets	-	15,150
Inventory	71,911	39,752
Total current assets	169,868	145,642
Fixed assets, net of depreciation	6,985	8,935
Other assets		
Patent pending	13,935	-
Total other assets	13,935	-
Total assets	$ 190,788	$ 154,577
LIABILITIES AND DEFICIT		
CURRENT LIABILITIES:		
Accounts payable and accrued liabilities	$ 52,564	$ 13,100
Accrued interest	245,115	171,908
Notes payable - related parties	12,548	124,237
Convertible notes payable, current portion	1,069,448	596,515
Notes payable	118,500	135,000
Derivative liabilities	-	130,103
Total current liabilities	1,498,175	1,170,863
LONG-TERM LIABILITIES:		
Convertible notes payable, net of discounts and current portion	-	192,237
Notes payable	190,000	40,000
Total long-term liabilities	190,000	232,237
Total liabilities	1,688,175	1,403,100
DEFICIT		
Series A Preferred at $0.00001 par value, 3,000,000 shares authorized, 3,000,000 and 1,000,000 issued and outstanding, respectively	30	10
Series B Preferred at $0.00001 par value, 100,000,000 shares authorized, 20,000,000 issued and outstanding	200	200
Common stock at $0.00001 par value: 900,000,000 shares authorized,23,137,979 and 56,013 shares issued and outstanding, respectively	231	56
Additional paid-In capital	15,387,552	7,779,959
Accumulated deficit	(17,205,242)	(9,060,878)
Total Radiant stockholders’ deficit	(1,817,229)	(1,280,709)
Non-controlling interest in subsidiary	319,843	32,186
Total Radiant stockholders’ deficit	(1,497,386)	(1,248,523)

TOTAL LIABILITIES AND DEFICIT	$ 190,788	$ 154,577

The accompanying notes are an integral part of these consolidated financial statements.

THE RADIANT CREATIONS GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Year Ended February 29, 2016		For the Year Ended February 28, 2015	
REVENUES	$	216,382	$	526,652
COST OF SERVICES		22,133		64,603
GROSS PROFIT		194,249		462,049
Operating Expenses:				
General and administrative expenses		980,155		727,566
Compensation		1,232,511		3,420,143
Depreciation		1,950		1,800
Inventory write-off		-		3,676
Total operating expenses		2,214,616		4,153,185
Operating loss		(2,020,367)		(3,691,1360)
Other Income (Expense):				
Interest expense		(594,931)		(628,110)
Bad debt recovery		-		195,534
Loss on modification of convertible debt		(5,506,688)		-
Loss on purchase of intellectual property from related party		(17,800)		(726,400)
Gain/(loss) on derivative liabilities		(187,208)		609,558
Total other expense, net		(6,306,627)		(549,418)
NET LOSS	$	(8,326,994)	$	(4,240,554)
LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST IN SUBSIDIARY	$	182,630	$	565
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(8,144,364)	$	(4,239,989)
NET LOSS PER COMMON SHARE - Basic and Diluted	$	(1.10)	$	(104.79)
Weighted Common Shares Outstanding - Basic and Diluted		7,394,910		40,463

The accompanying notes are an integral part of these consolidated financial statements.

THE RADIANT CREATIONS GROUP, INC.
CONSOLIDATED STATEMENT OF DEFICIT

	Preferred Shares								
	Series A	Series B	Par Value	Common Shares	Par Value	Additional Paid in Capital	Accumulated Deficit	Non-controlling Interest	Total Deficiency
Balance as of February 28, 2014	**-**	**-**	**$ -**	**43,417**	**$ -**	**$ 3,651,286**	**$ (4,820,889)**	**$ -**	**$ (1,169,603)**
Common stock issued for conversion of debt	-	-	-	25,604	-	215,150	-	-	215,150
Common stock issued for services	-	-	-	2,992	-	19,524	-	-	19,524
Reclassification of derivative to additional paid in capital upon conversion of debt	-	-	-	-	-	107,172	-	-	107,172
Cancellation of common stock	-	-	-	(16,000)	-	-	-	-	-
Fair value of options vested	-	-	-	-	-	3,193,006	-	-	3,193,006
Preferred stock issued	1,000,000	20,000,000	210	-	-	476,190	-	-	476,400
Issuance of common stock of subsidiary	-	-	-	-	-	117,631	-	32,751	150,382
Net loss for the year							(4,239,989)	(565)	(4,240,554)

Balance as of February 28, 2015	**1,000,000**	**20,000,000 $**	**210**	**56,013 $**	**- $**	**7,779,959 $**	**(9,060,878) $**	**32,186**	**$ (1,248,523)**
Common stock issued with debt	-	-	-	12,600	-	27,207	-	-	27,207
Common stock issued in satisfaction of debt	-	-	-	282,944	17	182,522	-	-	182,539
Common stock issued for cash	-	-	-	18,196,422	167	129,973	-	-	130,140
Common stock issued in satisfaction of executive compensation	-	-	-	4,590,000	46	536,954	-	-	537,000
Fair value of options vested	-	-	-	-	-	414,517	-	-	414,517
Loss on modification of convertible debt	-	-	-	-	-	5,506,688	-	-	5,506,688
Issuance of common stock of subsidiary	-	-	-	-	-	568,274	-	470,287	1,038,561
Preferred shares issued for the purchase of intellectual property from related party	2,000,000	-	20	-	-	17,800	-	-	17,800
Reclassification of derivative to additional paid in capital upon conversion of debt	-	-	-	-	-	223,679	-	-	223,679

Net loss for the year	-	-	-	-	-	-	(8,144,364)	(182,630)	(8,326,994)
Balance as of February 29, 2016	**3,000,000**	**20,000,000**	**$ 230**	**23,137,979**	**$ 231**	**$ 15,387,552**	**$ (17,205,242)**	**$ 319,843**	**$ (1,497,386)**

The accompanying notes are an integral part of these consolidated financial statements.

THE RADIANT CREATIONS GROUP, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS

	For the Year Ended February 29, 2016	For the Year Ended February 28, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Loss	$ (8,326,994)	$ (4,240,554)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation Expense	1,950	1,800
Loss on purchase of intellectual property from a related party	17,800	726,400
Loss on modification of convertible debt	5,506,688	-
(Gain)/Loss on derivative liabilities	187,208	(609,558)
Amortization of debt discounts	507,191	618,110
Default interest added to convertible notes payable	-	10,000
Stock based compensation	978,724	3,212,910
Write off of inventory	-	3,676
Write off of intangible asset	-	210
Bad debt recovery	-	(195,534)
Changes in operating assets and liabilities:		
Inventory	(32,159)	24,949
Notes receivable	11,547	51,045
Reserves	(20,077)	(3,265)
Prepaid expenses and other current assets	7,400	(6,740)
Accounts payable and accrued interest	53,424	150,786
NET CASH USED IN OPERATING ACTIVITIES	(1,107,298)	(255,764)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of fixed assets	-	(1,767)
Purchase of patent pending	(13,935)	-
NET CASH USED IN INVESTING ACTIVITIES	(13,935)	(1,767)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Cash borrowings from convertible debt	-	110,440
Cash payments on convertible debt	(70,000)	(31,000)
Cash borrowings from related parties	-	12,493
Cash payments on related party debt	(124,237)	(129,986)
Cash borrowings from notes payable	160,000	50,000
Cash payments on notes payable	(26,500)	(10,000)
Capital contribution	-	-
Cash proceeds from sale of common stock of subsidiary	1,038,970	150,002
Cash proceeds from issuance of common shares	130,140	-
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,108,373	151,949
NET CHANGE IN CASH	(12,860)	(105,582)
Cash at Beginning of Year	15,293	120,875
Cash at End of Year	$ 2,433	$ 15,293

SUPPLEMENTAL CASH FLOW INFORMATION:		
Cash paid for interest	$ 40,190	$ 42,250
Cash paid for income taxes	$ -	$ -
NON-CASH FINANCING AND INVESTMENT ACTIVITIES:		
Debt discount	$	$ 507,211
Conversion of convertible debt and accounts payable to common shares	$ 166,700	$ 215,150
Reclassification of derivative to additional paid in capital	$ -	$ 107,172
Issuance of preferred stock in exchange for common stock	$ -	$ 476,400

The accompanying notes are an integral part of these audited consolidated financial statements.

THE RADIANT CREATIONS GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – Organization and Significant Accounting Policies

Nature of Business

Radiant Creations Group, Inc. ("the Company") holds an exclusive license for the use of certain assets and processes related to innovative technologies in skin protection and enhancement, which consist of various proprietary products including an anti-aging and revitalizing skin cream generally sold under the "Radiant Creations" label. The Company's principal business is the development and marketing of unique and proprietary scientific technologies and cosmetic and over-the-counter personal enhancement products and devices and currently sells its products exclusively over the internet to customers located globally.

NIT Enterprises, Inc. ("NITE") was incorporated in the state of Delaware on May 12, 2014 and is doing business in the State of Florida. As of February 29, 2016, NITE is majority owned by the Company and was formed to permit Radiant Creations Group to "spin-off" the Nucleotide ("NA") technology it holds.

NITE's mission is to improve public safety and to provide a new measure of protection for commercial, industrial, and personal products that enhance the longevity of living and non-living substances based upon unique proprietary NA technologies. This new technology is the infusion of ingredients, known as nucleotides, into a multiplicity of common products enhanced by their presence. The nucleotides were derived by atomic level research that demonstrates their ability to provide Ultraviolet (UV) rays screening capability at the molecular level.

In March 2016, the Company transferred a portion of its interest and no longer holds a controlling interest in NITE.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its controlled subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Non-controlling Interest in Consolidated Financial Statements

Through February 29, 2016, the Company holds a controlling interest in NIT and reports amounts attributable to non-controlling interest as separate components of deficit and net loss. (see Note 3.)

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company's significant estimates include the valuation of stock-based compensation and derivative liabilities, estimates for future charge-backs, and allowance for slow moving or obsolete inventory.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. As of February 29, 2016 and February 28, 2015, the Company had no cash equivalents.

Inventory

Inventory consists of finished goods and is valued at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Provision for potentially obsolete or slow moving inventory is made based on management analysis or inventory levels and future sales forecasts.

Property and Equipment

Property and equipment are stated at cost, net of depreciation provided by use of a straight-line method over the estimated useful lives of the assets, of five years. The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable.

Basic and diluted net loss per share

Basic loss per share is computed using the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the dilutive effects of common stock equivalents on an "as if converted" basis. As of February 29, 2016, the number of potentially dilutive shares consisted of 25,562,556 shares underlying convertible debt as well as options to acquire 30,440 shares. As of February 28, 2015, the number of potentially dilutive shares consisted of 225,731 shares underlying convertible debt and options to acquire 30,440 shares. For the year ended February 29, 2016 and 2015, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

Related parties

The Company follows subtopic ASC 850, Related Party Disclosure, for the identification of related parties and disclosure of related party transactions.

Revenue Recognition

The Company follows guidance under ASC 605, Revenue Recognition, in determining when to report income from operations. The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery and acceptance has occurred, the price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Revenue recognized by the Company normally occurs upon shipment of our product to the customer.

Cost of Revenue

Amounts recorded as cost of revenue relate to direct expenses incurred in order to fulfill orders of our products. Such costs are recorded as incurred. Our cost of revenue consists primarily of the cost of product; charge backs and refunds; and the cost of product samples.

Cash flows reporting

The Company follows ASC 230, Statement of Cash Flows, for cash flows reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method ("Indirect method") as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net loss to reconcile it to net cash flows from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net loss that do not affect operating cash receipts and payments.

Share-based Expense

ASC 718, *Compensation – Stock Compensation*, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, *Equity – Based Payments to Non-Employees.* Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

Share-based expense for the year ended February 29, 2016 and 2015 was $978,724 and $3,212,910, respectively.

Income Taxes

The Company utilizes the asset and liability method to measure and record deferred income tax assets and liabilities. Deferred tax assets and liabilities reflect the future income tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company follows the provisions of Accounting for Uncertainty in Income Taxes, which clarified the accounting for uncertainties in tax positions and required that the Company recognizes in its financial statements the impact of an uncertain tax position, if that position has more likely than not chance of not being sustained on audit, based on technical merits of that position.

The Company is subject to the United States federal and state income tax examinations by the tax authorities for the 2015, 2014, and 2013 tax years.

Recently issued accounting pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

NOTE 2 – Going Concern

The accompanying financial statements have been prepared on the basis of accounting principles applicable to a “going concern”, which assume that the Company will continue in operation for at least one year and will be able to realize its assets and discharge its liabilities in the normal course of operations.

Several conditions and events cast substantial doubt about the Company’s ability to continue as a going concern. The Company has a working capital deficit of $1,328,307 as of February 29, 2016 and has incurred net losses since inception. The Company’s future capital requirements will depend on numerous factors including, but not limited to, executing its marketing and business plans and the pursuit of business opportunities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 – Non-controlling Interest

NIT Enterprises, Inc. was incorporated in the state of Delaware on May 12, 2014 and is doing business in the State of Florida. The Company is under common control with the management of Radiant Creations Group and was formed to permit Radiant Creations Group to “spin-off” the Nucleotide technology it holds. As of February 29, 2016, the Company holds 54.2% of NIT and 45.8% is held by non-controlling interests.

In March 2016, the Company transferred three third-party notes payable totaling $245,000, plus accrued interest to NIT Enterprises, Inc., its minority-owned subsidiary. In addition, the Company cancelled $425,000 in intercompany loans from NIT Enterprises, Inc, to the Company in exchange for 5,000,000 shares of NIT Enterprises, Inc. held by the Company as a Founder of NIT Enterprises. As a result, the Company no longer has controlling interest in NITE.

NOTE 4 – Notes Payable

Notes payable
The Company has two notes with outstanding balances as of February 29, 2016 of $75,000 and $2,500 which are subject to annual interest of 15% and matured on November 29, 2014 and January 31, 2015, respectively.

In April 2015, the Company issued a note payable in the amount of $150,000 for cash. The note matures in 24 months and accrues interest at an annual rate of 12%. The holder of the note also received 12,000 shares of common stock with a fair value of $33,000 based on the trading price of the shares on the date of issuance. The Company allocated $27,049 of the proceeds from the note to the common stock, which was recorded as a discount against the debt to be amortized through maturity. As of February 29, 2016, the note is carried at $150,000.

In October 2014, the Company issued a demand note in the amount of $50,000 for cash. The note is due on demand and accrues interest at an annual rate of 12%. During the year ended February 29, 2016, the Company repaid $20,250 which includes $1,250 in interest. As of February 29, 2016 and February 28, 2015, the principle balance on the note was $31,000 and $50,000, respectively.

In July 2014, the Company issued a note payable in the amount of $40,000 for cash. The note matures in 36 months and accrues interest at an annual rate of 10%, payable quarterly. As of February 29, 2016 and February 28, 2015, the principle balance remaining on the note was $40,000, respectively.

Notes payable - related parties

In July 2014, the Company issued a note payable in the aggregate amount of $250,000 for the purchase of intellectual property from a commonly owned entity. Because of the common ownership, the intellectual property was not marked to fair value and the Company recognized a loss for the amount of the notes, which is included in loss on acquisition of intellectual property from a commonly controlled entity on the consolidated statement of operations for the year ended February 29, 2016. The note was non-interest bearing, matured in 24 months from issuance, and required principal payments of at least $25,000 every 180 days. During the years ended February 29, 2016 and February 28, 2015, the Company made payments in the amounts of $116,337 and $133,663, respectively; and as of February 29, 2016 and February 28, 2015, the outstanding balance of the note was $0 and $116,337, respectively.

In September 2014, the Company issued a note in the amount of $7,900 for cash. The note was payable in two years from issuance, and accrued interest, payable monthly, at an annual rate of 10%. During the year ended February 29, 2016, the Company repaid the note in full. As of February 29, 2016 and February 28, 2015, the principle balance remaining on the note was $0 and $7,900, respectively.

At various times during the year ended February 29, 2016, the Company received an aggregate of $31,709 from a related party for operating expenses and repaid $19,162 in the same period. The obligation is considered a non-interest bearing, demand note payable and the balance at February 29, 2016 was $12,548.

NOTE 5 – Convertible Notes Payable

Note Date	Maturity Date	Face Amount	Eligible for Conversion	Conversion Date	Amounts Converted / Cash Paid*	Balance Outstanding
05/21/2013	09/20/2016	$900,448	06/15/2013	N/A 09/19/2013 11/20/2013	$31,000* $100,000 $70,000	$869,448 $769,448 **$699,448**
06/27/2013	$100,000 due 12/12/2014 (in default) $270,000 no due date	$370,000	06/27/2013	-	-	**$370,000**
11/19/2013		$78,500	05/19/2014	06/13/2014 07/01/2014 07/11/2014 07/21/2014	$12,000 $12,000 $15,000 $19,500	$66,500 $54,500 $39,500 $20,000

	08/21/2014	$10,000				$30,000
		Default				
				11/19/2014	$7,235	$22,765
				12/01/2014	$5,635	$17,130
				12/12/2014	$6,395	$10,735
				12/16/2014	$5,780	$4,955
				01/23/2015	$4,955	**$ -0-**
12/17/2013		$32,500	06/15/2014	-	-	$32,500
	09/21/2014	$16,250				$48,750
		Default				
				02/02/2015	$4,430	$44,320
				02/05/2015	$6,030	$38,290
				03/06/2015	$3,515	$34,775
				03/09/2015	$3,515	$31,260
				03/16/2015	$3,515	$27,445
				03/23/2015	$3,760	$23,985
				03/24/2015	$9,560	$14,425
				03/31/2015	$2,675	$11,750
				03/31/2015	$11,750	**$-0-**
01/27/2014		$32,500	07/26/2014	-	-	$32,500
		$16,250				$48,750
		Default				
				04/07/2015	$7,495	$41,225
				04/08/2015	$10,685	$30,570
				04/15/2015	$10,500	$20,070
				04/22/2015	$11,540	$8,530
				04/29/2015	$8,000	$530
	10/29/2014			05/01/2015	$530	**$-0-**
07/08/2014		$21,150	01/04/2015	-	-	$21,150
	04/09/2015	$10,575				$31,725
		Default				
				05/07/2015	$4,320	$27,405
				05/14/2015	$3,165	$24,240
				05/19/2015	$2,400	$21,840
				05/26/2015	$1,820	$20,020
				06/15/2015	2,655	$17,365
				06/17/2015	2,655	$14,710
				06/25/2015	2,655	$12,055
				06/26/2015	2,510	$9,545
				06/29/2015	2,235	$7,310
				07/01/2015	2,235	$5,075
				07/06/2015	2,235	$2,840
				07/09/2015	2,095	$745
				07/14/2015	745	**$-0-**
09/03/2014		$32,500	03/03/2015	-	-	$32,500
	06/05/2015	$16,250				$48,750
		Default				
			08/05/2015	N/A	$48,750*	**$-0-**

09/10/2014	09/10/2016	$35,000	09/10/2014		-	$35,000
				03/27/2015	$3,320	$31,680
				03/31/2015	$3,802	$21,878
				04/07/2015	$4,373	$23,506
				04/15/2015	$5,013	$18,493
				04/22/2015	$6,630	$11,863
				05/01/2015	$4,608	$7,255
				05/07/2015	$5,232	$2,023
				05/15/2015	$2,023	**$-0-**
01/12/2015		$16,000	07/11/2015	-	-	$16,000
	10/14/2015	$8,000				$24,000
		Default				
				N/A	$21,250*	$2,750
		Note paid off at discount		N/A	$ 2,750	**$-0-**
Totals		**$1,595,923**	**-**	**-**	Converted **$ 425,475** Cash paid **$ 101,000***	**$1,069,448**

Convertible notes payable

During 2011, 2012 and 2013, the Company obtained loans totaling $720,000. These loans were unsecured and bore interest at 10%. In 2013, the loans (including accrued interest of $140,448 in the amount of $900,448 were converted to a Convertible Note Payable due to Southwest Financial bearing interest at 10% per annum. Following cash payments of $31,000 and conversions to common stock of $170,000 later in fiscal 2013, the Company owed $699,448. The notes were initially convertible at the option of the Holder at fixed rate of $93.75 per share and matured on September 20, 2015. In September 2014, the conversion rate was amended to a fixed rate of $0.05 per share. The Company recorded additional expense of $3,845,935 as a result of the reduction in conversion price which is recorded as a loss on modification of convertible debt. The Company paid no principal cash payments on these notes during the years ended February 29, 2016 and February 28, 2015. The principle balance of the note was $699,448 at February 29, 2016 and February 28, 2015.

As of February 28, 2015, the Company owed convertible notes totaling $370,000 to third parties including accrued interest of another $4,041. Interest is 10% annually and is to be paid currently. The notes may be converted at the option of the Holder at a fixed rate of $93.75 per share. In February 2014, the notes were amended to modify the conversion rate to $3.75 per share. In August 2015, the conversion rate was further reduced to $0.05 per share. The Company recorded additional expense of $1,660,753 as a result of the reduction in conversion price which is recorded as a loss on modification of convertible debt. The principle balance of the notes as of February 29, 2016 and February 28, 2015 was $370,000 in the aggregate, respectively, and the notes are due on demand.

On November 19, 2013, the Company signed a convertible note agreement with a third party in which the party loaned $78,500 subject to annual interest of 8%. The note matured on August 21, 2014 and was convertible into the Company's common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion. On May 18, 2014, the note became convertible and the embedded conversion option required derivative accounting for the variable conversion rate. On May 18, 2014, a derivative liability of $64,146 was recorded as a debt discount and amortized over the term of the note. The embedded conversion option of the note also tainted the other outstanding convertible notes. During the twelve months ended February 28, 2015, the lender converted $78,500 in principle and $10,000 in default interest in exchange for 8,432 shares of common stock and the note was paid in full.

On December 17, 2013, the Company signed a convertible note agreement with a third party in which the party loaned $32,500 subject to annual interest of 8%. The note matured on September 21, 2014 and was convertible into the Company's common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion. On December 1, 2014, default interest in the amount of $16,250 was added to the principle balance of the note. During the year ended February 29, 2016, the lender converted $38,290 in principle in exchange for 31,801 shares of common stock and during the twelve months ended February 28, 2015, the lender converted $10,460 in principle in exchange for 6,973 shares of common stock. The principle balance of the note was $0 and $38,290 as of February 29, 2016 and February 28, 2015, respectively.

On January 27, 2014, the Company signed a convertible note agreement with a third party in which the party loaned $32,500 subject to annual interest of 8%. The note matured on October 29, 2014 and was convertible into the Company's common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion. On July 26, 2014, a derivative liability of $23,228 was recorded as a debt discount and amortized over the term of the note. During the twelve months ended February 28, 2015, default interest of $16,250 was added to the principle balance of the note. During the year ended February 29, 2016, the lender converted $51,350 in principle and interest in exchange for 43,421 shares of common stock and the note was paid in full. The principle balance of the note was $48,750 as of February 28, 2015.

On July 8, 2014, the Company signed a convertible note agreement with a third party in which the party loaned $21,150 subject to annual interest of 8%. The note matured on April 9, 2015 and was convertible into the Company's common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion. During the twelve months ended February 28, 2015, default interest of $10,575 was added to the principle balance of the note. During the year ended February 29, 2016, the lender converted $31,725 in principle in exchange for 134,751 shares of common stock and the note was paid in full. The principle balance of the note as of February 28, 2015 was $31,275.

On September 3, 2014, the Company signed a convertible note agreement with a third party in which the party loaned $32,500 subject to annual interest of 8%. The note matured on June 5, 2015 and was convertible into the Company's common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion. During the twelve months ended February 28, 2015, default interest of $16,250 was added to the principle balance of the note. In the same period, the Company paid $48,750 in cash and the note was paid in full. The principle balance of the note as of February 28, 2015 was $48,750.

On September 9, 2014, the Company executed a $35,000 Convertible Promissory Note bearing interest on the unpaid balance at the rate of 12% on the original principal amount. The principle amount due on the note shall be prorated based upon the consideration actually received by the Company, plus an approximate 10% original issue discount that is prorated based upon the consideration actually received as well as any other interest or fees. The Maturity Date is two years from the Effective Date of each payment and is the date upon which the principal sum of this Note, as well as any unpaid interest and other fees, shall be due and payable. The conversion price was the lesser of $56.25 or 60% of the lowest trade price in the 25 trading days previous to the conversion. During the year ended February 29, 2016, the lender converted $43,565 in principle in exchange for 57,504 shares of common stock and the note was paid in full. During the twelve months ended February 28, 2015, default interest of $16,250 was added to the principle balance of the note and an additional derivative liability of $9,264 was recorded. The balance of the note as of February 28, 2015 was $35,000.

On January 12, 2015, the Company signed a convertible note agreement with a third party in which the party loaned $16,000 subject to annual interest of 8%. The note matured on October 14, 2015 and was convertible into the Company's common stock after 180 days from the date of issuance at 58% of the average of the lowest prices of the common stock during the ten days preceding the date of conversion. On July 11, 2015, the note became convertible and the embedded conversion option required derivative accounting to the variable conversion rate. During the twelve months ended February 28, 2015, default interest of $8,000 was added to the principle balance of the note and an additional derivative liability of $4,636 was recorded. During the year ended February 29, 2016, the Company satisfied the remaining principle of $24,000 in the form of cash payment of $21,250 and the balance of $2,750 was recorded against the discount on the note for early payment. The principle balance of the note as of February 28, 2015 was $24,000.

Amortization expense on the debt discounts for the year ended February 29, 2016 amounted to $507,191 and notes are carried at $1,069,448. Amortization expense on the debt discounts for the twelve months ended February 28, 2015 amounted to $618,110 and notes were carried at $788,752, net of unamortized discounts of $507,211.

NOTE 6– Derivative Liabilities

The Company records the fair value of the conversion features of the convertible notes disclosed in Note 4 in accordance with ASC 815, Derivatives and Hedging. The fair value of the derivative liability was calculated using a multi-nominal lattice model. The fair value of the derivative liability is revalued on each balance sheet date with corresponding gains and losses recorded in the consolidated statements of operations. During the year ended February 29, 2016, the Company recorded a loss on the change in fair value of derivative liability of $187,208.

The following table summarizes the changes in derivative liabilities during the year ended February 29, 2016:

Balance as of February 28, 2015	**$**	**130,103**
Fair value of embedded conversion derivative liability at issuance		280,784
Reclassification of derivatives upon conversion or redemption of convertible debt		(223,679)
Unrealized derivative losses included in other expense		187,208
Ending balance as of February 29, 2016	**$**	**-0-**

The Company determined that the instruments embedded in the convertible note should be classified as liabilities and recorded at fair value due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The fair value of the instruments was determined using a multinomial lattice model based on the following assumptions:

- The projected volatility curve for each valuation period was based on the historical volatility of the Company and ranged from 191% to 198%.
- An event of default would occur 5% of the time, increasing 1.00% per month to a maximum of 10%,
- The monthly trading volume would average $175,000 to $136,000 and would increase at 1% per month. The variable conversion price of 58% of ask-bid or close prices over 10 trading days have effective discount rates of 42.42%,
- The variable conversion price of the lesser of: (i) $0.045, or (ii) 60% of the lowest trade price over 25 trading days would have effective discount rates of 47.92% to 47.64%
- The Note Holders would automatically convert fixed and variable conversion prices (with full ratchet resets) the notes at the stock price for the convertible Note if the registration was effective and the Company was not in default, and conversion price reset events are assumed every 3 months.

NOTE 7 – Equity

During the year ended February 29, 2016 and February 28, 2015, stock-based compensation expense recognizing the fair value of vested stock options was $414,517 and $3,193,006, respectively. Expected future expense related to the expected vesting of options is $45,332. The fair value of the options was determined using a Black Scholes model, with the following assumptions:

- Volatility: 188% to 288%
- Risk-free interest rate: 0.43% to 0.58%
- Zero expected dividends
- Expected term is the simplified method
- Exercise prices are based on option agreements
- Common stock price on the valuation date

The following table summarizes the Company's stock options activity for the years ended February 29, 2016 and February 28, 2015:

	Options		Weighted Average Exercise Price	Aggregate Intrinsic Value	Exercisable	Weighted Average Remaining Life
Balance, February 28, 2014	**-**	**$**	**-**	**-**	**-**	**-**
Granted	30,440		0.00			
Expired						
Exercisable						
Balance, February 28, 2015	**30,440**		**0.00**		**22,440**	**4.29**
Granted						
Expired						
Exercisable						
Balance, February 29, 2016	**30,440**	**$**	**0.00**		**22,440**	**3.79**

On August 24, 2015, the Board of Directors of the Company approved a reverse split of the Company's commons stock at a ratio of one for one thousand two hundred and fifty (1,250) shares, (1-for-1,250). As of August 24, 2015, (prior to the Reverse Split), we had 439,445,822 shares of common stock outstanding and 460,554,178 common shares available for issuance. Upon effectiveness (September 25, 2015) of the Reverse Split, the Company remained authorized to issue 900,000,000 common shares and had 351,557 shares outstanding with the ability to issue 899,648,443 additional common shares. The Company's financial statements for all periods presented have been retroactively adjusted to reflect the stock split made effective on September 25, 2015.

The table below illustrates the capitalization of our outstanding shares as of September 25, 2015, before and after the Reverse Split.

Capitalization	Prior to the Reverse Split	After the Reverse Split
Common stock (1)		
Authorized	900,000,000	900,000,000
Issued and Outstanding	439,445,822	351,557
Available for Issuance	460,554,178	899,648,443
Series A Preferred stock (2,4)		
Authorized	3,000,000	3,000,000
Issued and Outstanding	3,000,000	3,000,000
Available for Issuance	-	-
Series B Preferred stock (3,4)		
Authorized	20,000,000	20,000,000
Issued and Outstanding	20,000,000	20,000,000
Available for Issuance	-	-

(1) Each one (1) share of our Common Stock entitles the holder to one (1) vote per share on all matters submitted to a vote of our stockholders.

(2) Each one (1) share of our Series A Preferred Stock entitles the holder to two hundred (200) votes per share on all matters submitted to a vote of our stockholders.

(3) Each one (1) share of our Series B Preferred Stock entitles the holder to one (1) vote per share on all matters submitted to a vote of our stockholders.

(4) As a result of the 3,000,000 Series A Preferred shares and 20,000,000 Series B Preferred shares held by Biodynamic Molecular Technologies, LLC, a commonly controlled entity, it holds an aggregate of 620,000,000 common shares or 59% of the votes, which entitle it to determine the outcome of all matters submitted to a vote of our stockholders.

During the year ended February 29, 2016, the Company issued 282,944 shares of common stock upon the conversion of debt, for an aggregate value of $182,539. (see Note 4)

During the year ended February 29, 2016, the Company issued 12,600 shares of common stock in connection with the issuance of a note payable. (see Note 4)

During the year ended February 29, 2016, the Company issued 18,196,422 shares of common stock for cash for a value of $130,140.

During the year ended February 29, 2016, the Company converted $537,000 in accrued executive compensation to 4,590,000 shares of common stock of the Company.

During the year ended February 29, 2016, the Company received $100,000 from an investor in exchange for shares of common stock in the Company equal to 5% of the total outstanding shares of common stock as of January 31, 2016. As of February 29, 2016, 1,683,000 shares have been issued.

During the year ended February 29, 2016, the Company issued 2,000,000 shares of its Series A Preferred Stock to related parties as consideration for the purchase of intellectual property. The fair value of the shares of $17,800, based on the value of the control feature, was recorded as expense during the year ending February 29, 2016.

During the twelve months ended February 28, 2015, the Company issued 25,604 shares of common stock upon the conversion of debt, for an aggregate value of $215,150.

During the twelve months ended February 28, 2015, the Company issued 2,992 shares of common stock as compensation for services for a value of $19,524.

Prior to the twelve months ended February 28, 2015, the Company granted 30,440 options to employees and directors with a term of 5 years and are exercisable at prices ranging from $0.098 to $0.127 per share. 8,000 options vested immediately while the remaining 22,440 options vest at a rate of 33% on the grant date, 33% one year from the grant date and the remaining 33% two years from the grant date. The fair value of the options was determined using a Black Scholes model. The total grant date fair value of the options amounted to $3,630,278 of which $414,517 and $3,193,006 was recorded as stock compensation expense during the twelve months ended February 29, 2016 and February 28, 2015, respectively.

On September 9, 2014 and October 13, 2014 Biodynamic Molecular Technologies, LLC (a commonly controlled shareholder) agreed to cancel a total of 16,000 common shares of the Company in exchange for 1,000,000 shares of Series A Preferred stock and 20,000,000 shares of Series B Preferred stock.

The Company estimated the fair value of the 20,000,000 shares of common stock based on the trading price on date of the exchange, and the fair value of the preferred stock using a probability weighted expected return method (PWERM) and recorded expense equal to the excess of the fair value of the preferred stock over the common stock of $476,000, which is included in loss on acquisition of intellectual property from a commonly controlled entity on the consolidated statements of operations.

Stock compensation expense totaled $978,724 and $3,212,910 for the twelve months ended February 29, 2016 and February 28, 2015, respectively.

NIT Enterprises, Inc.

During the year ended February 29, 2016, NIT Enterprises issued 110,000 shares of common stock as compensation for services rendered for a value of $11.

During the year ended February 29, 2016, NIT Enterprises issued 4,092,000 shares of common stock for cash for a value of $1,038,970.

During the year ended February 29, 2016, NIT Enterprises issued 30,982,000 preferred shares to investors according to the terms provided in NIT's cash subscription agreement. The shares were issued at par value.

During the year ended February 29, 2016, NIT Enterprises issued 1,000,000 Series A, Super-Voting preferred shares to a founder for a value of $100.

During the year ended February 29, 2015, NIT Enterprises issued 3,800,000 shares of common stock for services rendered for a value of $380.

During the year ended February 29, 2015, NIT Enterprises issued 560,000 shares of common stock for cash for a value of $150,002.

During the year ended February 29, 2015, NIT Enterprises issued 560,000 preferred shares to investors according to the terms provided in NIT's cash subscription agreement. The shares were issued at par value.

Note 8 – Income Tax Provision

Deferred Tax Assets

At February 29, 2016, the Company had net operating loss ("NOL") carry–forwards for Federal income tax purposes of $9,431,893 that may be offset against future taxable income through 2035. No tax benefit has been reported with respect to these net operating loss carry-forwards because the Company believes that the realization of the Company's net deferred tax assets of approximately $5,850,000 was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are offset by a full valuation allowance.

Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realization. The valuation allowance increased approximately $2,757,948 and $1,139,172 for the years ended February 29, 2016 and February 28, 2015, respectively.

Components of deferred tax assets are as follows:

	Feb 29, 2016	Feb 28, 2015
Net deferred tax assets – non-current:		
Expected income tax benefit from NOL carry-forwards	$ 5,849,782	$ 3,091,834
Less valuation allowance	(5,849,782)	(3,091,834)
Deferred tax assets, net of valuation allowance	$ -	$ -

Income Tax Provision

A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income tax provision is as follows:

	For the Fiscal Year Ended February 29, 2016	For the Fiscal Year Ended February 28, 2015
Federal statutory income tax rate	34.0	34.0
Change in valuation allowance on net operating loss carry-forwards	(34.0	(34.0)
Effective income tax rate	0.0	0.0

NOTE 9 – Commitments and Contingencies

Acquisition and Assignment

On June 25, 2013, the Company purchased certain assets from The Renewable Corporation, a related party. The purchases included their license, certain assets and processes to innovative technologies in skin protection from the sun, industrial UV sources (such as welding), and reducing collateral damage from medical radiation treatment which consists of various patented skin products generally under the "Radiant Creations" label.

The license purchased is with Dr. Yin-Xiong Li, MD, Ph.D. to his patent in Enhanced Broad-Spectrum UV Radiation Filters and Methods as disclosed and claimed in U.S. Patent No. US Patent # 6,117,846 - Nucleic acid filters and US Patent Application # 20080233626 - Enhanced broad-spectrum UV radiation filters and methods, and the following international filings European Application # 07811023.6, and Australian Application # 2007281485 and as trade secrets associate with the above listed intellectual property and trade secrets and potential patent applications for an anti-aging skin rejuvenation cream, an acne OTC treatment, a wrinkle reduction cream, BioSalt redistribution technology using supplements. The License Agreement, as of June 25, 2013 has added an addendum to it allowing Renewable to transfer the license agreement to The Radiant Creations Group.

The various patented skin products acquired include all the patented technologies that strips out the four nucleotide code molecules from DNA strands and uses them in a system that can provide up to 99% protection from DNA damage, which is the cause of aging and skin cancer. A second technology is the delivery system to house the nucleotides, and also, a hydration agent that is time released to infuse uniform hydration into the skin for up to 10 hours. The resulting products are a DNA based SPF-30 day cream; an anti-aging and rejuvenating night cream featuring the hydration system, Chinese herbs, and aloe; a medical radiation protection and healing cream for use by dermatologists in radiation therapy for skin cancer and a rejuvenating DNA protection cream for the tanning bed industry for DNA damage protection.

Other terms of the Agreement include:

Radiant shall pay all future intellectual property costs for the Licensed Patent, including all costs incident to the United States and foreign applications, patents and like protection, including all costs incurred for filing, prosecution, issuance and maintenance fees as well as any costs incurred in filling continuations, continuations-in-part, divisional s or related applications and any improvements, re-examination or reissue proceedings.

Radiant agrees to appoint Li to the Radiant Advisory Board with compensation for such appointment to be commensurate with other members when remuneration is commended.

Radiant agrees to offer Li an Executive position for any subsidiary corporation responsible for operating the above Licensed Products for which the subsidiary becomes profitable. As part of the position, salary and executive benefit compensation will be offered, terms to be negotiated at time of offer.

Radiant shall pay Li a royalty of twenty-two percent (22%) of the Net Profit of the Licensed Product ("the Royalty") made during the term of this Agreement.

The Royalty owed to Li shall be calculated on a quarterly calendar basis ("Royalty Period") and shall be payable no later than thirty (30) days after the termination of the preceding full Royalty Period i.e., commencing on the first (1st) day of January, April, July and October, except that the first and last Royalty Periods may be "short," depending on the effective date of this Agreement.

For each Royalty Period, Radiant shall provide Li with a written royalty statement in a form acceptable to Li. Such royalty statement shall be certified as accurate by a duly authorized officer of Radiant. Such statements shall be furnished to Li regardless of whether any Licensed Products were sold during the Royalty Period or whether any actual Royalty was owed. As of February 29, 2016 and February 28, 2015, no amounts were paid or accrued under the Agreement.

Litigation

The Company may become involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, excepts as discussed herein, the ultimate disposition of these matters will not have a material adverse effect on the Company's financial position, results of operations, or liquidity. As of February 29, 2016, the Company is not involved in any material legal matters.

NOTE 10 – Related Party Transactions

During the year ended February 29, 2016, the Company enlisted a related party, Renewable Bioscience Holdings, Inc., to act as a bookkeeping and vending agent for the Company's majority owned subsidiary, NIT Enterprises, Inc. For the year ended February 29, 2016, the Company's agent disbursed $438,572 in expenses on behalf of the Company which primarily consisted of staff and executive compensation, investor relations expenses, reimbursements of travel costs, and $21,322 paid to the Company's executive officers.

At various times during the year ended February 29, 2016, the Company received notes and advances from a related party for operating expenses. The obligation is considered non-interest bearing, demand note payable and the balance at February 29, 2016 was $12,548.

During the year ended February 29, 2016, the Company issued a non-interest bearing demand note receivable to a related party in the amount of $4,700. During the year ended February 29, 2016, the remaining balance of $4,700 was paid in full.

In September 2014, the Company issued a note in the amount of $7,900 to a commonly controlled entity for cash. The note was payable in two years from issuance, and accrued interest, payable monthly, at an annual rate of 10%. As of February 29, 2016 and February 28, 2015, the principle balance was $0 and $7,900, respectively.

In July 2014, the Company issued a note payable in the aggregate amount of $250,000 for the purchase of intellectual property from a commonly owned entity. Because of the common ownership, the intellectual property was not marked to fair value and the Company recognized a loss for the amount of the notes, which is included in loss on acquisition of intellectual property from a commonly controlled entity on the consolidated statements of operations. The note is non-interest bearing, matures in 24 months from issuance, and requires principal payments of at least $25,000 every 180 days. During the years ended February 29, 2016 and February 28, 2015, the Company made payments in the amounts of $116,337 and $133,663, respectively; and as of February 29, 2016 and February 28, 2015, the outstanding balance of the note was $0 and $116,337, respectively.

On March 3, 2014, the Company executed employment agreements for its Officers that included annual compensation in equal amounts of $156,000 annually, a $75,000 signing bonus, and 6,000,000 shares of common stock options. Prior to the year ending February 29, 2016, the Officers had elected to forego their annual compensation; however, the Company's board of directors elected to pay by issuing $537,000 in related compensation to its Officers. During the year ended February 29, 2016, the Company converted the deferred compensation to 4,590,000 shares of common stock with a fair value of $537,000 based on the trading price of the common stock as of the date of grant.

During the year ended November 30, 2014, the Company issued 2,000,000 shares of its Series A Preferred Stock to related parties as consideration for services rendered. The fair value of the shares of $17,800, based on the value of the control feature, was recorded as expense during the year ending February 29, 2016.

NOTE 11 – Subsequent Events

On March 1, 2016, the Company accepted the resignation of Manpreet Singh Thaper, Director and COO. There were no disagreements between Mr. Singh Thaper and the Registrant on any matter relating to the Company's operations, policies or practices.

On March 7, 2016, Gary R. Smith, our Chairman of the Board of Directors, resigned his position with the Company. There were no disagreements between Mr. Smith and the Company on any matter relating to the Company's operations, policies or practices. Effective on the same date, to fill the vacancy left by the removal of Mr. Smith, the Board of Directors appointed Michael S. Alexander, Chief Executive Officer and President, as the Registrant's Chairman of the Board Directors.

On March 11, 2016, the Company executed a General Release and Settlement Agreement with the former Director/CEO, Gary R. Smith and other related parties, terms include:

Transfer of Notes and Inter-Company Loans - The Company transferred three Third-Party Notes Payable totaling $245,000 plus accrued interest to NIT Enterprises, Inc., its minority-owned subsidiary, and cancelled $425,000 in intercompany loans from NIT Enterprises, Inc., to the Company in exchange for 5,000,000 shares of NIT Enterprises, Inc. held by the Company as a Founder of NIT Enterprises. As a result, the Company no longer has controlling interest in NITE.

The Parties agreed to the cancellation of all related Executive Employment Agreements of both the Company and NIT Enterprises, Inc.

The Parties agreed to transfer of ownership of Gary R. Smith's interest in BioDynamic Molecular Technologies, LLC (the "Control Shareholder" of the Company) to Michael S. Alexander, Director and CEO and Gary D. Alexander, Director and CFO of the Company in equal proportions.

The Parties agreed to allow the Company to relocate its office; and to the cancellation of related office utility agreements and accounts payable held in the name of the Company.

Subsequent to February 29, 2016, the Company issued 2,089,999 shares of common stock to investors for cash.

Subsequent to February 29, 2016, the Company issued 1,760,000 shares of common stock to consultants as compensation for services rendered.

Subsequent to February 29, 2016, the Company issued 1,358,136 shares of common stock to note holders in exchange for principle and interest.

On April 4, 2016, the Company cancelled 1,530,000 shares of common stock held by the Company’s former Director/CEO.

On May 24, 2016, the Company’s Board of Directors agreed that the Company would issue 67,824 shares of its common stock to a related party to extinguish a demand note payable in the amount of $12,548.

ITEM 6 - DESCRIBE THE ISSUER'S BUSINESS, PRODUCTS AND SERVICES

The Radiant Creations Group, Inc., formerly known as Nova Mining Corporation (the "Company") was incorporated in Nevada on December 29, 2005. From inception, the Company's principal business activity was the acquisition and exploration of mineral resources. On June 20, 2013, following a change of control and subsequent acquisition of an exclusive license agreement, certain assets and processes to innovative technologies in skin protection and enhancement, which consist of various proprietary products including an anti-aging and revitalizing skin cream generally under the "Radiant Creations" label, the Company changed its principal business to the development and marketing of unique and proprietary scientific technologies and cosmetic and over-the-counter personal enhancement products and devices.

CURRENT MARKETING PLAN

Radiant's product marketing plan is based on a 4-part strategy for year 2016. Our strategy is designed to maximize cash inflow from the existing revenues while increasing growth through engaging additional marketing affiliate partners, acquiring additional investment capital infusion and new product development.

The steps are as follows:

1. Current Trial Sale Marketing Program: Our current trial sale marketing program is an on-line continuity model that requires an initial high level of investment capital inflow in order to achieve an extremely high level of gross revenue outflow upon reaching the 3rd billing cycle.

Our customers receive the product on the first trial order at a competitive $4.95 trial price (the shipping costs). Radiant engages a professional marketing company that acquires the customers at a flat rate acquisition fee, priced between $45-$50 per customer. If the customer chooses to keep the initial product then they are charged the remaining full price of $89.98 continuing on a monthly basis until the customer chooses to cancel the subscription offer.

The explosive profitability comes into play when the customer is repeatedly retained. The longer one can retain the customer the more profitable the sale becomes as a result of the "one time" (initial) customer acquisition cost. Industry averages for a customer retained longer than three billing cycles is considered an extremely good customer. Additional factors that keep customer retention levels high include good Company/Customer communications, timely customer service response time for customers inquiring about the products and most importantly, an effective product with impressive packaging, which Radiant has achieved.

2. Ad Exchange Marking Group: Management initially engaged Ad Exchange Group (Ad Exchange) as they presented an easy program entry concept including a secondary partnership with an ancillary wrinkle removing eye serum product. The majority of on-line trial sale marketing campaigns are sold in two-part steps. In our program, Revivasol is Step 1 and the wrinkle removing eye serum product is Step 2. Currently, Radiant's Eye Serum product to be paired with Revivasol is underdevelopment and is expected to be completed by mid-summer. Working with Ad Exchange Group, we were able to partner with the ancillary product that allowed us to put Revivasol into the hands of the consumer and create a strong reoccurring revenue stream for Radiant Creations.

Using Ad Exchange Group, Radiant is currently running approximately 300 new customer sales per week (traffic). Company sales with Ad Exchange Group began in early February, 2016. Initial and reoccurring sales and the continual customer retention has produced over $100,000 gross revenue per month through the month of May, 2016.

Thereafter, this model based on one Radiant product (Revivasol) will continue to grow organically for six months before plateauing at a level of above $150,000 gross revenue per month or $450,000 gross revenue per quarter. Although confident in our ability to expand the Revivasol revenue stream using the Ad Exchange Group platform Management prefers to diversify its risk by engaging a secondary marking company and expanding its affiliate marketing strategy.

3. Jumbleberry Marketing Group: In order to diversify the Company marketing risk and further expand our affiliate marketing revenue stream, Management has undertaken a strategic partnership with Jumbleberry Marketing Group. Jumleberry offers a successful trial sale marketing platform similar to that of Ad Exchange Group which requires Radiant to utilize a two-step product marketing model. Therefore, Radiant has engaged its manufacture AIG Technologies to formulate a fresh and unique wrinkle removing eye serum.

Jumbleberry has been in the online marketing industry for several years and has built a strong affiliate marketing system that allows customers like Radiant to reach numbers as high as 5,000 new customers per week. With the completion of our step-2 product by early to mid-summer, 2016, Radiant will begin running new customer traffic through the Jumbleberry's platform in addition to existing traffic we continue to run with Ad Exchange Group. Management intends to initially run an additional 700 new sales per week increasing to 900-1200 new sales thereafter. These new sales numbers will produce gross revenue approaching $1,000,000 per quarter through the Jumleberry platform alone.

4. Additional Ad-on Products: With the completion of the Company's 2-step products and engaging the Jumbleberry marketing program Management intends to add two additional ancillary products to both the Ad Exchange Group and the Jumbleberry marketing platforms. The products will include Revivasol SPF-15 and Revivasol Spot Remover. Minimal set-up costs are required for both affiliate marketers as these products will be added onto the existing website sales pages with no additional customer acquisition costs incurred. The products will not be sold as part of the trial sale but as a one-time purchase for customers that desire these products as an up-sell item. Management anticipates these additional sales will produce in excess of $250,000 in gross revenue per quarter with a extremely high profit margins as a result of not requiring additional customer acquisition costs or marketing expenses other than website up-grades.

Conclusion and Investment Capital Requirements: The key factors to accomplishing Managements goals are already completed. The completed tasks include; achieving initial revenue utilizing Ad Exchange Marketing Group, prepayment of product costs expenses for up to 14,000 additional units of Revivasol formula to be manufactured, establishing a successful and effective customer service system, engagement of Jumbleberry Marketing Group as affiliate marketing partner, completed formulas for Revivasol SPF-15 and Revivasol Spot Remover and access to sufficient merchant processing capacity to sustain increase gross revenue.

Fulfillment: Our Fulfillment services provide real time tracking capability, which allows Radiant Creations to fulfill most orders within 24 hours. As such, we are able to guarantee timely, accurate shipments at great rates. Regardless of quantity, time frame, or weight Radiant Creations will process orders efficiently. The knowledgeable Fulfillment Center Staff works from early in the morning to late at night every day making sure each and every order ships timely and successfully.

COMPETITION

The skin care and online marketing businesses are characterized by vigorous competition throughout the world. Brand recognition, quality, performance and price have a significant impact on consumers' choices among competing products and brands. We compete against a number of companies, some of which have substantially greater resources than we do.

Our principal competitors consist of large, well-known, multinational manufacturers and distributors of skin care products, most of which market and sell their products under multiple brand names. We also face competition from a number of independent brands, as well as some retailers that have developed their own beauty brands.

RESEARCH AND DEVELOPMENT

We incurred no research and development expenditures to date.

INTELLECTUAL PROPERTY

We own an exclusive licensing agreement with Dr. Yin-Xiong Li, M.D., Ph.D and one trademark under the name "Revivasol".

Date and State (or Jurisdiction) of Incorporation: December 29, 2005 – Nevada

The issuer's primary and secondary SIC Codes: 2844
The issuer's fiscal year end date: 2/28

ITEM 7 - DESCRIBE THE ISSUER'S FACILITIES

At February 29, 2016, the Company maintained its corporate headquarters at 2401 PGA Blvd, suite 272, Palm Beach Gardens, FL 33410. The facilities consisted of high profile corporate office space. On March 11, 2016, following the separation of The Radiant Creations Group, Inc and NIT Enterprises, Inc. The Board of Directors, in an effort to reduce overhead cost, relocated its offices to a modest executive office suite.

ITEM 8 - OFFICER, DIRECTORS AND CONTROL PERSONS

Full Name: Michael S. Alexander
Title: Chief Executive Officer, President and member of the Board of Directors
Business Address: Center for Innovation, 10380 SW Village Center Drive, Suite 352
Port Saint Lucie, FL

Biography – Mr. Michael S. Alexander, began his career as Manager of Treasure Coast Private Equity, LLC (a Florida based investment firm with a focus on technology and the development of start-up companies with patented or prototype products. He participated in equity market trading, including small cap, micro cap and options, and assisted with the acquisition and advancement of existing technologies. During his time there he was invited to become a Board Member for Greenwood Gold Mining, a start-up public company until December of 2010. In December, 2011, Mr. Alexander became the CEO and President of Technology River Investments, the predecessor to Treasure Coast Private Equity where Mr. Alexander was incremental in the acquisition and management of numerous portfolio investments on behalf of Technology River. Mr. Alexander is a graduate of the University of North Florida, and holds a Bachelor of Science degree in Business Administration (Finance).

Full Name: Gary D. Alexander
Title: Chief Financial Officer, Secretary and member of the Board of Directors
Business Address: Center for Innovation, 10380 SW Village Center Drive, Suite 352
Port Saint Lucie, FL

Biography – Gary D. Alexander is currently founder and chairman of Golden River Capital, LLC a Florida based investment services firm. He has more than 35 years of experience in the fields of accounting and investments. His knowledge and skills include initiating public and private offerings for small companies, professional accounting services with “go-public” transactions, private placement syndications, mergers, and acquisitions. He has extensive experience in forensic and reconstructive accounting and litigation matters and has led and/or participated in projects including the cosmetic industry,aviation, automotive, petroleum, internet services, telephone and VoIP industries, medical technologies, and the entertainment, music and film industries.

Previously, Mr. Alexander was chairman of Technology Rive Investments, a Florida based private equity firm that specializes in providing debt and equity resources for privately owned business seeking expansion capital. In May 2014, the Company was combined with Golden River Capital.

From January 2013 through February 2014, he served as officer and member of the board of directors of CarolCo Pictures, Inc. a/k/a Brick Top Productions, Inc. a film production company (CRCO) and in June 2013 he became director, chief financial officer and corporate secretary of The Radiant Creations Group, Inc. (RCGP) and subsidiaries. Through an asset acquisition, the company is designed to capitalize on innovative patented DNA based technologies to be used in the cosmetic and medical industries.

In December 1977, Mr. Alexander earned a Bachelor of Business Administration (Accounting) degree from Florida Atlantic University, Boca Raton, FL. He owned and operated a successful CPA practice from April 1982 through December 2006.

Throughout his career, he has served as a member and chair of numerous charitable organizations to help provide needed services in his local community.

The table below summarizes all compensation awarded to, earned by, or paid to our executive officers by any person for all services rendered in all capacities to us for the fiscal years ended February 29, 2016 and February 28, 2015.

Name and principal position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Comp ($)	Non-Qualified Deferred Comp Earnings ($)	All Other Comp ($)	Total ($)
Michael S. Alexander	2015	*156,000	75,000		-	-		-	231,000
Michael S. Alexander	2016	156,000	-		-	-	-	-	156,000
Gary D. Alexander	2015	156,000	75,000		-		-	-	231,000
Gary D. Alexander	2016	156,000	-		-	-	-	-	156,000

There are employment contracts with the Company’s officers at this time. There are no employment contracts with the Directors at this time.

Legal/Disciplinary History.

Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None.

The following table sets forth, as of June 24, 2016, information about the beneficial ownership of our capital stock with respect to each person known by The Radiant Creations Group, Inc. Inc. to own beneficially more than 5% of the outstanding capital stock, each director and officer, and all directors and officers as a group.

Title of Class	**Name and Address of Beneficial Owner**	**Number of Shares of Preferred Stock**	**Percentage of Preferred Stock**(1) (2)	**Number of Shares of Common Stock**	**Percentage of Common Stock**(3)
Series A Preferred Super-voting control, non-convertible	BioDynamic Molecular Technologies, LLC Port Saint Lucie, FL	3,000,000	100%	-	-
Preferred Series B –non-convertible	BioDynamic Molecular Technologies, LLC Port Saint Lucie, FL Beneficial Owners: Michael S. Alexander, Chief Executive Officer, President and member of the Board of Directors - 10,000,000 Shares Gary D. Alexander, Chief Financial Officer, Secretary and member of the Board of Director - 10,000,000 Shares	20,000,000	100%	-	-
Common Stock	Michael S. Alexander, Chief Executive Officer, President and member of the Board of Directors	-	-	1,538,440	0.07
Common Stock	Gary D. Alexander, Chief Financial Officer, Secretary and member of the Board of Director	-	-	1,582,400	0.07
Common Stock	BioDynamic Molecular Technologies,	-	-	4,000	Less than

LLC Beneficial Owner: Private Investor Port Saint Lucie, FL	5%

1) The above percentages are based 3,000,000 on shares of Series A preferred stock outstanding as of July 1, 2016.
2) The above percentages are based 20,000,000 on shares of Series B preferred stock outstanding as of July 1, 2016.
3) The above percentages are based 23,137,979 on shares of common stock outstanding as of July 1, 2016.

ITEM 9 - THIRD PARTY PROVIDERS

1. Counsel

Brenda Lee Hamilton
Hamilton and Associates
101 Plaza Real South
Suite 202-N
Boca Raton, FL 33432
Ph. 561-416-8956

2. Accountant or Auditor

Financials prepared by Management

3. Investor Relations Consultant

None

4. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement - the information shall include the telephone number and email address of each advisor.

None

ITEM 10 - ISSUER CERTIFICATION

I, Michael S. Alexander, certify that:

1. I have reviewed this annual report of The Radiant Creations Group, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: July 1, 2016

/s/ Michael S. Alexander
Michael S. Alexander
Chief Executive Officer
(Principal Executive Officer)

I, Gary D. Alexander, certify that:

1. I have reviewed this annual report of The Radiant Creations Group, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: July 1, 2016

/s/ Gary D. Alexander
Gary D. Alexander
Chief Financial Officer
(Principal Financial Officer)